Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 (mut) measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, includi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Haematological Malignancy ‐ Clinical
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://ncbi.nlm.nih.gov/pubmed/32458446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16722
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares